Department of Anesthesiology and Pain Medicine, United Hospital, Seoul, Republic of Korea.
Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
PLoS One. 2020 Dec 10;15(12):e0243873. doi: 10.1371/journal.pone.0243873. eCollection 2020.
We investigated the impact of postreperfusion syndrome (PRS) on hyperglycemia occurrence and connecting (C) peptide release, which acts as a surrogate marker for insulin resistance, during the intraoperative period after graft reperfusion in patients undergoing living donor liver transplantation (LDLT) using propensity score (PS)-matching analysis.
Medical records from 324 adult patients who underwent elective LDLT were retrospectively reviewed, and their data were analyzed according to PRS occurrence (PRS vs. non-PRS groups) using the PS-matching method. Intraoperative levels of blood glucose and C-peptide were measured through the arterial or venous line at each surgical phase. Hyperglycemia was defined as a peak glucose level >200 mg/dL, and normal plasma concentrations of C-peptide in the fasting state were taken to range between 0.5 and 2.0 ng/mL.
After PS matching, there were no significant differences in pre- and intra-operative recipient findings and donor-graft findings between groups. Although glucose and C-peptide levels continuously increased through the surgical phases in both groups, glucose and C-peptide levels during the neohepatic phase were significantly higher in the PRS group than in the non-PRS group, and larger changes in levels were observed between the preanhepatic and neohepatic phases. There were higher incidences of C-peptide levels >2.0 ng/mL and peak glucose levels >200 mg/dL in the neohepatic phase in patients with PRS than in those without. PRS adjusted for PS with or without exogenous insulin infusion was significantly associated with hyperglycemia occurrence during the neohepatic phase.
Elucidating the association between PRS and hyperglycemia occurrence will help with establishing a standard protocol for intraoperative glycemic control in patients undergoing LDLT.
本研究通过倾向性评分(PS)匹配分析,探讨了再灌注后综合征(PRS)对肝移植供体肝再灌注后术中高血糖发生及连接肽(C)释放的影响,C 肽释放可作为胰岛素抵抗的替代标志物。
回顾性分析了 324 例行择期活体肝移植的成年患者的病历资料,根据PRS 的发生情况(PRS 组与非 PRS 组),采用 PS 匹配方法对其进行分析。通过动脉或静脉线在每个手术阶段测量术中血糖和 C 肽水平。高血糖定义为血糖峰值>200mg/dL,空腹时正常 C 肽浓度范围为 0.5-2.0ng/mL。
PS 匹配后,两组间受体和供体-移植物的术前和术中资料无显著差异。虽然两组患者的血糖和 C 肽水平在手术各阶段均持续升高,但 PRS 组患者的新肝期血糖和 C 肽水平明显高于非 PRS 组,且新肝期与术前肝期之间的水平变化更大。PRS 组新肝期 C 肽水平>2.0ng/mL 和血糖峰值>200mg/dL 的发生率高于非 PRS 组。PRS 与新肝期高血糖的发生与 PS 调整后是否使用外源性胰岛素输注显著相关。
阐明 PRS 与高血糖发生之间的关系,有助于建立活体肝移植患者术中血糖控制的标准方案。